NLS Pharmaceutics
NLSP
NLSP
4 hedge funds and large institutions have $29.7K invested in NLS Pharmaceutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$9K |
| 2 |
AC
2
Armistice Capital
New York
|
$714 |
Top Sellers
| 1 |
1
Citadel Advisors
Miami,
Florida
|
$0 |
| 2 |
TRCT
2
Tower Research Capital (TRC)
New York
|
$0 |
| 3 |
3
Renaissance Technologies
New York
|
$12K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $12K | -$1.03K | -43 | -8% |
|
|
2
UBS Group
Zurich,
Switzerland
| $9K | +$2.74K | +116 | +44% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $8K | – | – | – |
|
|
AC
4
Armistice Capital
New York
| $714 | +$714 | +30,410 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$31K | -541 | Closed |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | -$5K | -92 | Closed |
|